10x Genomics(US:TXG) Prnewswire·2025-01-12 17:00Company Performance - The company reported preliminary, unaudited FY 2024 revenue of approximately $611 million and Q4 2024 revenue of approximately $165 million, representing 9% sequential growth [4] - Q4 2024 revenue of $165 million showed a 10% decrease compared to the corresponding prior year period [10] - FY 2024 revenue of $610.8 million represented a 1% decrease from the prior year [10] - The company's cumulative instruments sold increased to over 7,000 by the end of 2024, including over 5,800 Chromium instruments, over 800 Visium instruments, and over 400 Xenium instruments [10] - Cash, cash equivalents, and marketable securities stood at approximately $393 million as of December 31, 2024 [10] Revenue Breakdown - Q4 2024 instruments revenue was approximately $24.4 million, showing 28% sequential growth but a 37% decrease compared to the prior year period [10] - Q4 2024 consumables revenue was approximately $133.5 million, with 6% sequential growth but a 5% decrease compared to the prior year period [10] - Q4 2024 services revenue was approximately $7.1 million, showing 12% sequential growth and 35% growth over the prior year period [10] - FY 2024 instruments revenue was approximately $92.7 million, a 25% decrease from the prior year [10] - FY 2024 consumables revenue was approximately $493.4 million, representing 3% growth over the prior year [10] - FY 2024 services revenue was approximately $24.6 million, showing 57% growth over the prior year [10] Product-Specific Revenue - Q4 2024 Chromium instruments revenue was approximately $10.9 million, while Spatial instruments revenue was approximately $13.4 million [10] - Q4 2024 Chromium consumables revenue was approximately $97.7 million, while Spatial consumables revenue was approximately $35.8 million [10] - FY 2024 Chromium instruments revenue was approximately $35.2 million, while Spatial instruments revenue was approximately $57.5 million [10] - FY 2024 Chromium consumables revenue was approximately $372.3 million, while Spatial consumables revenue was approximately $121.1 million [10] Company Overview - The company is a life science technology firm focused on accelerating the mastery of biology and advancing human health [7] - Its integrated solutions include instruments, consumables, and software for single cell and spatial biology [7] - The company's products support breakthroughs in oncology, immunology, neuroscience, and other fields [7] Investor Relations - The company will participate in the 43rd Annual J P Morgan Healthcare Conference, with a live webcast available on January 13, 2025 [1] - The company discloses material non-public information through SEC filings, its website, press releases, conference calls, webcasts, and social media accounts [3]